Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/9551
Full metadata record
DC FieldValueLanguage
dc.contributor.authorJohnston, Colin Ien
dc.contributor.authorCooper, Mark Een
dc.contributor.authorNicholls, G Men
dc.date.accessioned2015-05-15T22:41:36Z
dc.date.available2015-05-15T22:41:36Z
dc.date.issued1992-04-01en
dc.identifier.citationJournal of Hypertension; 10(4): 393-7en
dc.identifier.govdoc1316406en
dc.identifier.otherPUBMEDen
dc.identifier.urihttp://ahro.austin.org.au/austinjspui/handle/1/9551en
dc.description.abstractPoints of agreement: (1) In IDDM, hypertension occurs in patients who have already developed nephropathy, probably in the microalbuminuric phase. (2) Hypertension is an important accelerator of the development of diabetic nephropathy. (3) Hypertension, obesity and NIDDM are often associated, and insulin resistance is commonly observed in all three states. (4) Antihypertensive therapy retards the development of diabetic nephropathy in IDDM and reduces proteinuria in NIDDM. (5) The choice of antihypertensive agent in the diabetic patient must be based upon the efficacy of the drug as well as avoidance of side effects including deleterious influence on glucose, insulin and lipid levels and renoprotection. (6) Carefully conducted long-term comparative trials between different classes of antihypertensive drugs in microalbuminuric IDDM and NIDDM patients are essential. Points of major controversy: (1) Detection of IDDM patients prone to the development of diabetic nephropathy can be performed by measuring specific parameters such as erythrocyte Na(+)-Li+ countertransport activity. (2) Insulin resistance is a pathogenic mechanism rather than purely an association with hypertension and obesity. (3) A certain class of antihypertensive agents--ACE inhibitors--confers a specific renoprotective effect in diabetic nephropathy, in addition to its effects upon systemic blood pressure. (4) Reduction of blood pressure should be considered in the normotensive microalbuminuric diabetic patient. (5) Microalbuminuria is a sufficient 'surrogate endpoint' for the progression of renal failure.en
dc.language.isoenen
dc.subject.otherAnimalsen
dc.subject.otherAntihypertensive Agentsen
dc.subject.otherDiabetes Mellitusen
dc.subject.otherDiabetes Mellitus, Experimentalen
dc.subject.otherDiabetic Nephropathiesen
dc.subject.otherHumansen
dc.subject.otherHypertensionen
dc.subject.otherRatsen
dc.subject.otherRats, Inbred SHRen
dc.subject.otherSocieties, Medicalen
dc.titleMeeting report of the International Society of Hypertension Conference on Hypertension and Diabetes.en
dc.typeJournal Articleen
dc.identifier.journaltitleJournal of Hypertensionen
dc.identifier.affiliationDepartment of Medicine, Austin Hospital, Heidelberg, Victoria, Australiaen
dc.description.pages393-7en
dc.relation.urlhttps://pubmed.ncbi.nlm.nih.gov/1316406en
dc.type.austinJournal Articleen
item.grantfulltextnone-
item.languageiso639-1en-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.openairetypeJournal Article-
item.fulltextNo Fulltext-
item.cerifentitytypePublications-
Appears in Collections:Journal articles
Show simple item record

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.